These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28935078)

  • 21. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overlapping technique for hybrid percutaneous coronary intervention strategy utilising drug eluting stent and ABSORB bioresorbable vascular scaffold.
    Yew KL
    Int J Cardiol; 2015 Jan; 178():e8-e10. PubMed ID: 25205484
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Letter regarding "Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI".
    Granata F; Moscarella E; Varricchio A
    Int J Cardiol; 2015 Jul; 190():7-8. PubMed ID: 25912107
    [No Abstract]   [Full Text] [Related]  

  • 25. Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction.
    Miyazaki T; Panoulas VF; Sato K; Naganuma T; Latib A; Colombo A
    Int J Cardiol; 2014 Jun; 174(2):e72-4. PubMed ID: 24784914
    [No Abstract]   [Full Text] [Related]  

  • 26. One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: The PRAGUE-19 Study.
    Widimsky P; Petr R; Tousek P; Maly M; Linkova H; Vrana J; Hajsl M; Budesinsky T; Lisa L; Kocka V
    Circ Cardiovasc Interv; 2015 Dec; 8(12):e002933. PubMed ID: 26628591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient with non-ST-segment elevation myocardial infarction treated by Absorb bioresorbable scaffold implantation.
    Zasada W; Rzeszutko Ł; Dziewierz A; Dudek D
    Kardiol Pol; 2013; 71(10):1091-2. PubMed ID: 24197595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioresorbable scaffolds and STEMI: an ideal setting, but still vacant.
    Spaulding C
    EuroIntervention; 2020 Mar; 15(16):1397-1399. PubMed ID: 32200347
    [No Abstract]   [Full Text] [Related]  

  • 29. Real life experience with bioresorbable-polymer everolimus-eluting stents. Is this an answer in search of a question?
    Rahban Y; Kimmelstiel C
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):888-889. PubMed ID: 29148244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optical coherence tomography in STEMI with bioresorbable scaffold: possible cause of coronary flow impairment? A sub-study from the Prague 19 trial.
    Loffi M; Tousek P; Budesinsky T; Lisa L; Santangelo A; Widimsky P; Kocka V
    Heart Vessels; 2018 Nov; 33(11):1282-1287. PubMed ID: 29777297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioresorbable vascular scaffold implantation to bail out nail gun injury in ST-segment myocardial infarction.
    Schütz T; Krönig FP; Karmeinsky C; Weingärtner O
    Clin Res Cardiol; 2018 Jan; 107(1):87-90. PubMed ID: 28905244
    [No Abstract]   [Full Text] [Related]  

  • 32. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Further elucidation on "Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI".
    Yew KL
    Int J Cardiol; 2015 Jul; 191():170-1. PubMed ID: 25965626
    [No Abstract]   [Full Text] [Related]  

  • 34. A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study.
    Ielasi A; Campo G; Rapetto C; Varricchio A; Cortese B; Brugaletta S; Geraci S; Vicinelli P; Scotto di Uccio F; Secco GG; Poli A; Nicolini E; Ishida K; Latib A; Tespili M
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1855-1864. PubMed ID: 28935077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioresorbable Vascular Scaffold During ST-Elevation Myocardial Infarction: A Systematic Review.
    Picard F; de Hemptinne Q; Avram R; Ly HQ; L'Allier PL; Tanguay JF
    Can J Cardiol; 2017 Apr; 33(4):515-524. PubMed ID: 28343607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
    Diletti R; Karanasos A; Muramatsu T; Nakatani S; Van Mieghem NM; Onuma Y; Nauta ST; Ishibashi Y; Lenzen MJ; Ligthart J; Schultz C; Regar E; de Jaegere PP; Serruys PW; Zijlstra F; van Geuns RJ
    Eur Heart J; 2014 Mar; 35(12):777-86. PubMed ID: 24394380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.
    Cortese B; Ielasi A; Romagnoli E; Varricchio A; Cuculo A; Loi B; Pisano F; Corrado D; Sesana M; La Vecchia L; Summaria F; Tespili M; Silva Orrego P; Tognoni G; Steffenino G
    Am J Cardiol; 2015 Sep; 116(5):705-10. PubMed ID: 26100584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
    Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
    JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI.
    Yew KL
    Int J Cardiol; 2015; 186():74-6. PubMed ID: 25814348
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.